UniProt ID | GNAT3_HUMAN | |
---|---|---|
UniProt AC | A8MTJ3 | |
Protein Name | Guanine nucleotide-binding protein G(t) subunit alpha-3 | |
Gene Name | GNAT3 | |
Organism | Homo sapiens (Human). | |
Sequence Length | 354 | |
Subcellular Localization |
Cytoplasm . Dual ditribution pattern plasmalemmal pattern with apical region localization and cytosolic pattern with localization throughout the cytoplasm. |
|
Protein Description | Guanine nucleotide-binding protein (G protein) alpha subunit playing a prominent role in bitter and sweet taste transduction as well as in umami (monosodium glutamate, monopotassium glutamate, and inosine monophosphate) taste transduction. Transduction by this alpha subunit involves coupling of specific cell-surface receptors with a cGMP-phosphodiesterase; Activation of phosphodiesterase lowers intracellular levels of cAMP and cGMP which may open a cyclic nucleotide-suppressible cation channel leading to influx of calcium, ultimately leading to release of neurotransmitter. Indeed, denatonium and strychnine induce transient reduction in cAMP and cGMP in taste tissue, whereas this decrease is inhibited by GNAT3 antibody. Gustducin heterotrimer transduces response to bitter and sweet compounds via regulation of phosphodiesterase for alpha subunit, as well as via activation of phospholipase C for beta and gamma subunits, with ultimate increase inositol trisphosphate and increase of intracellular Calcium. GNAT3 can functionally couple to taste receptors to transmit intracellular signal: receptor heterodimer TAS1R2/TAS1R3 senses sweetness and TAS1R1/TAS1R3 transduces umami taste, whereas the T2R family GPCRs act as bitter sensors. Functions also as lumenal sugar sensors in the gut to control the expression of the Na+-glucose transporter SGLT1 in response to dietaty sugar, as well as the secretion of Glucagon-like peptide-1, GLP-1 and glucose-dependent insulinotropic polypeptide, GIP. Thus, may modulate the gut capacity to absorb sugars, with implications in malabsorption syndromes and diet-related disorders including diabetes and obesity.. | |
Protein Sequence | MGSGISSESKESAKRSKELEKKLQEDAERDARTVKLLLLGAGESGKSTIVKQMKIIHKNGYSEQECMEFKAVIYSNTLQSILAIVKAMTTLGIDYVNPRSAEDQRQLYAMANTLEDGGMTPQLAEVIKRLWRDPGIQACFERASEYQLNDSAAYYLNDLDRITASGYVPNEQDVLHSRVKTTGIIETQFSFKDLHFRMFDVGGQRSERKKWIHCFEGVTCIIFCAALSAYDMVLVEDEEVNRMHESLHLFNSICNHKYFSTTSIVLFLNKKDIFQEKVTKVHLSICFPEYTGPNTFEDAGNYIKNQFLDLNLKKEDKEIYSHMTCATDTQNVKFVFDAVTDIIIKENLKDCGLF | |
Overview of Protein Modification Sites with Functional and Structural Information | ||
* ASA = Accessible Surface Area
Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
---|---|---|---|---|---|
2 | Myristoylation | ------MGSGISSES ------CCCCCCHHH | 34.28 | - | |
35 | Acetylation | ERDARTVKLLLLGAG HHHHHHHHHHHHCCC | 32.57 | 163903 | |
44 | Phosphorylation | LLLGAGESGKSTIVK HHHCCCCCCCHHHHH | 51.07 | 20873877 | |
46 | Ubiquitination | LGAGESGKSTIVKQM HCCCCCCCHHHHHHE | 54.42 | 21890473 | |
46 | Ubiquitination | LGAGESGKSTIVKQM HCCCCCCCHHHHHHE | 54.42 | 23000965 | |
47 | Phosphorylation | GAGESGKSTIVKQMK CCCCCCCHHHHHHEE | 27.22 | 20873877 | |
48 | Phosphorylation | AGESGKSTIVKQMKI CCCCCCHHHHHHEEE | 33.02 | 29514088 | |
51 | Ubiquitination | SGKSTIVKQMKIIHK CCCHHHHHHEEEECC | 40.60 | 23000965 | |
54 | Ubiquitination | STIVKQMKIIHKNGY HHHHHHEEEECCCCC | 35.69 | 22817900 | |
89 | Phosphorylation | LAIVKAMTTLGIDYV HHHHHHHHHCCCCCC | 24.59 | - | |
90 | Phosphorylation | AIVKAMTTLGIDYVN HHHHHHHHCCCCCCC | 15.20 | - | |
95 | Phosphorylation | MTTLGIDYVNPRSAE HHHCCCCCCCCCCHH | 10.54 | - | |
108 | Phosphorylation | AEDQRQLYAMANTLE HHHHHHHHHHHHCHH | 5.98 | 21214269 | |
113 | Phosphorylation | QLYAMANTLEDGGMT HHHHHHHCHHCCCCC | 23.22 | 21214269 | |
155 | Phosphorylation | LNDSAAYYLNDLDRI CCCCHHHHCCCHHHE | 8.36 | - | |
190 | Phosphorylation | GIIETQFSFKDLHFR CEEEEEEEECCCEEE | 22.90 | 24719451 | |
206 | Phosphorylation | FDVGGQRSERKKWIH EECCCCCCCHHHHCH | 33.59 | 23401153 | |
321 | Phosphorylation | KEDKEIYSHMTCATD CCCHHHHHHCCCCCC | 16.67 | 22210691 | |
327 | Phosphorylation | YSHMTCATDTQNVKF HHHCCCCCCCCCCCC | 41.55 | 22210691 | |
345 | Ubiquitination | AVTDIIIKENLKDCG HHHHHHHHHHHCCCC | 30.09 | 32015554 |
Modified Location | Modified Residue | Modification | Type of Upstream Proteins | Gene Name of Upstream Proteins | UniProt AC of Upstream Proteins | Sources |
---|---|---|---|---|---|---|
Oops, there are no upstream regulatory protein records of GNAT3_HUMAN !! |
Modified Location | Modified Residue | Modification | Function | Reference | ||
---|---|---|---|---|---|---|
Oops, there are no descriptions of PTM sites of GNAT3_HUMAN !! |
* Distance = the distance between SAP position and PTM sites.
Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of GNAT3_HUMAN !! |
Interacting Protein | Gene Name | Interaction Type | PPI Reference | Domain-Domain Interactions |
---|---|---|---|---|
Oops, there are no PPI records of GNAT3_HUMAN !! |
Kegg Drug | ||||||
---|---|---|---|---|---|---|
DrugBank | ||||||
There are no disease associations of PTM sites. |
loading...